GSA Capital Partners LLP Acquires 16,792 Shares of LeMaitre Vascular, Inc. $LMAT

GSA Capital Partners LLP increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 378.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,234 shares of the medical instruments supplier’s stock after buying an additional 16,792 shares during the period. GSA Capital Partners LLP’s holdings in LeMaitre Vascular were worth $1,722,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. ProShare Advisors LLC raised its stake in shares of LeMaitre Vascular by 9.5% during the fourth quarter. ProShare Advisors LLC now owns 74,110 shares of the medical instruments supplier’s stock worth $6,010,000 after buying an additional 6,403 shares during the last quarter. Wakefield Asset Management LLLP bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth approximately $1,130,000. Thrivent Financial for Lutherans raised its stake in shares of LeMaitre Vascular by 492.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 88,950 shares of the medical instruments supplier’s stock worth $7,214,000 after buying an additional 73,925 shares during the last quarter. Pittenger & Anderson Inc. raised its stake in shares of LeMaitre Vascular by 156.7% during the fourth quarter. Pittenger & Anderson Inc. now owns 11,450 shares of the medical instruments supplier’s stock worth $929,000 after buying an additional 6,990 shares during the last quarter. Finally, Vest Financial LLC raised its stake in shares of LeMaitre Vascular by 19.8% during the fourth quarter. Vest Financial LLC now owns 67,450 shares of the medical instruments supplier’s stock worth $5,470,000 after buying an additional 11,171 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 6th. Wells Fargo & Company boosted their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Barrington Research boosted their price target on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

Insider Activity

In related news, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the transaction, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This trade represents a 56.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 269,891 shares of company stock worth $28,969,086 in the last ninety days. Company insiders own 7.40% of the company’s stock.

LeMaitre Vascular Stock Up 0.5%

Shares of NASDAQ LMAT opened at $101.33 on Wednesday. The stock has a market cap of $2.32 billion, a P/E ratio of 37.39, a P/E/G ratio of 2.80 and a beta of 0.60. The firm has a 50 day moving average price of $109.11 and a 200 day moving average price of $95.11. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular, Inc. has a 52-week low of $78.35 and a 52-week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be issued a dividend of $0.25 per share. The ex-dividend date is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s payout ratio is currently 36.90%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.